LEXEO Therapeutics Strengthens Management Team with Key Appointments LEXEO strengthens management team with key appointments to accelerate development of clinical-stage pipeline.
LEXEO Therapeutics Announces License Agreement and Consolidation of Pre-clinical Data Package Lexeo completes license of all intellectual property rights and pre-clinical data associated with Adverum's Friedreich's ataxia program.
LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies LEXEO Therapeutics, a fully integrated gene therapy company, launches with financing from Longitude Capital and Omega Funds.
Dec 2, 2020Slowing Late Infantile Batten Disease Late infantile Batten disease (CLN2 disease) is an autosomal recessive, neurodegenerative lysosomal storage disease caused by mutations...
